Clinical Trial Update: Real World-clinical Outcomes of Tucatinib, Trastuzumab, and Capecitabine Following Trastuzumab Deruxtecan (T-DXd) for the Treatment of HER2-positive Metastatic Breast Cancer.

View source ↗

Summary

This completed clinical trial assesses real-world outcomes of the tucatinib, trastuzumab, and capecitabine regimen in patients with HER2-positive metastatic bre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Enhertu (trastuzumab deruxtecan)
• HERCEPTIN (trastuzumab)
• Tukysa (tucatinib)
• Xeloda (capecitabine)

Snippet

Sponsor: Pfizer | Conditions: Metastatic HER2+ Advanced Breast Cancer | Status: COMPLETED